Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
Filed with ASX · · 3 pages · English
Melbourne, Australia; January 11, and New York, USA; January 10, 2021: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced additional results from the landmark DREAM-HF randomized controlled Phase 3 trial in 537 treated patients with chronic heart failure with reduced left ventricular ejection fraction (HFrEF) who rece
In the deck
Earlier from Mesoblast
- Mesoblast Update on COVID-19 ARDS Trial
- Trading halt
- Mesoblast Phase 3 Chronic Heart Failure Results
- Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
- Novartis and Mesoblast Remestemcel-L Collaboration
Later from Mesoblast
- Mesoblast Phase 3 Chronic Low Back Pain Results
- Mesoblast Raises US$110M Led By US Strategic Investor Group
- COVID ARDS Trial Topline 60-Day Results
- MSB Reports Q3 Financial Results and Operational Highlight
- Mesoblast Update on Chronic Low Back Pain Program
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast